Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2022 09:30 ET | Source: SciSparc Ltd

SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome

The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL AVIV, Israel, Aug. 01, 2022 (GLOBE NEWSWIRE)...
July 08, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
July 07, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a...
July 06, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Board of Directors to Promote Buyback Program of up to $1 Million

TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...
June 29, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
June 23, 2022 09:30 ET | Source: SciSparc Ltd

SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
June 15, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty,...
June 09, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc's Board of Directors Provides Strategic Decision

TEL AVIV, Israel, June 09, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of...
June 07, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.

TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
June 02, 2022 08:30 ET | Source: SciSparc Ltd

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction

No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...